<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7264656\results\search\disease\results.xml">
  <result pre="LiHuahttps://orcid.org/0000-0001-9644-67681lihua199988@hotmail.comLiuZhe2GeJunbo1ge.junbo@zs-hospital.sh.cn[1], Department of CardiologyShanghai Institute of Cardiovascular DiseasesShanghai Xuhui District" exact="Central" post="Hospital and Zhongshanâ€�Xuhui HospitalZhongshan HospitalFudan UniversityShanghaiChina[2], Department of MedicineBestNovo"/>
  <result pre="Li and Junbo Ge, Department of Cardiology, Shanghai Institute of" exact="Cardiovascular Diseases," post="Shanghai Xuhui District Central Hospital &amp;amp; Zhongshanâ€�xuhui Hospital, Zhongshan"/>
  <result pre="of Cardiology, Shanghai Institute of Cardiovascular Diseases, Shanghai Xuhui District" exact="Central" post="Hospital &amp;amp; Zhongshanâ€�xuhui Hospital, Zhongshan Hospital, Fudan University, 179"/>
  <result pre="original work is properly cited.file:JCMM-24-6558.pdf Abstract Abstract A cluster of" exact="pneumonia" post="(COVIDâ€�19) cases have been found in Wuhan China in"/>
  <result pre="stranded RNA was identified to be the aetiological virus (severe" exact="acute" post="respiratory syndrome coronavirus 2, SARSâ€�CoVâ€�2), which has a phylogenetic"/>
  <result pre="RNA was identified to be the aetiological virus (severe acute" exact="respiratory" post="syndrome coronavirus 2, SARSâ€�CoVâ€�2), which has a phylogenetic similarity"/>
  <result pre="was identified to be the aetiological virus (severe acute respiratory" exact="syndrome" post="coronavirus 2, SARSâ€�CoVâ€�2), which has a phylogenetic similarity to"/>
  <result pre="coronavirus 2, SARSâ€�CoVâ€�2), which has a phylogenetic similarity to severe" exact="acute" post="respiratory syndrome coronavirus (SARSâ€�CoV). SARSâ€�CoVâ€�2 transmits mainly through droplets"/>
  <result pre="2, SARSâ€�CoVâ€�2), which has a phylogenetic similarity to severe acute" exact="respiratory" post="syndrome coronavirus (SARSâ€�CoV). SARSâ€�CoVâ€�2 transmits mainly through droplets and"/>
  <result pre="SARSâ€�CoVâ€�2), which has a phylogenetic similarity to severe acute respiratory" exact="syndrome" post="coronavirus (SARSâ€�CoV). SARSâ€�CoVâ€�2 transmits mainly through droplets and close"/>
  <result pre="droplets and close contact and the elder or people with" exact="chronic" post="diseases are highâ€�risk population. People affected by SARSâ€�CoVâ€�2 can"/>
  <result pre="10.1111/jcmm.15364 1 BACKGROUND In late December 2019, a cluster of" exact="pneumonia" post="(COVIDâ€�19) cases with unidentified causes have been found in"/>
  <result pre="It is related to a positive stranded RNA virus (severe" exact="acute" post="respiratory syndrome coronavirus 2, SARSâ€�CoVâ€�2), which has a phylogenetic"/>
  <result pre="is related to a positive stranded RNA virus (severe acute" exact="respiratory" post="syndrome coronavirus 2, SARSâ€�CoVâ€�2), which has a phylogenetic similarity"/>
  <result pre="related to a positive stranded RNA virus (severe acute respiratory" exact="syndrome" post="coronavirus 2, SARSâ€�CoVâ€�2), which has a phylogenetic similarity to"/>
  <result pre="coronavirus 2, SARSâ€�CoVâ€�2), which has a phylogenetic similarity to severe" exact="acute" post="respiratory syndrome coronavirus (SARSâ€�CoV).1 From the beginning, COVIDâ€�19 was"/>
  <result pre="2, SARSâ€�CoVâ€�2), which has a phylogenetic similarity to severe acute" exact="respiratory" post="syndrome coronavirus (SARSâ€�CoV).1 From the beginning, COVIDâ€�19 was reported"/>
  <result pre="SARSâ€�CoVâ€�2), which has a phylogenetic similarity to severe acute respiratory" exact="syndrome" post="coronavirus (SARSâ€�CoV).1 From the beginning, COVIDâ€�19 was reported to"/>
  <result pre="fish and live wild animals.2 The subsequent evidence of clinician" exact="infection" post="suggests that SARSâ€�CoVâ€�2 can transmit from human to human.3"/>
  <result pre="transmit from human to human.3 Massive alveolar damage and progressive" exact="respiratory" post="failure may lead to death in severe cases, and"/>
  <result pre="history.6 According to a survey conducted by Chinese Centers for" exact="Disease" post="Control and Prevention on more than 40,000 COVIDâ€�19 patients,"/>
  <result pre="80Â years old) was around 50.8% and 14.8% of the" exact="total" post="number of deaths, respectively. No deaths occurred in the"/>
  <result pre="overseas.13 Asymptomatic cases with COVIDâ€�19 accounted for ~1% of the" exact="total" post="number of patients and the viral load of asymptomatic"/>
  <result pre="for ~1% of the total number of patients and the" exact="viral" post="load of asymptomatic patients was similar to that of"/>
  <result pre="viral load of asymptomatic patients was similar to that of" exact="symptomatic" post="patients, which indicated that asymptomatic patients also had the"/>
  <result pre="usually increase the possibility of infection.19, 20 To block the" exact="viral" post="transmission by isolation, wearing masks and other ways of"/>
  <result pre="ways of reducing close contact are recommended. 3 PATHOGENESIS 3.1" exact="Viral" post="genome information and viral origin Since COVIDâ€�19 outbreak, the"/>
  <result pre="contact are recommended. 3 PATHOGENESIS 3.1 Viral genome information and" exact="viral" post="origin Since COVIDâ€�19 outbreak, the novel coronavirus SARSâ€�CoVâ€�2 causing"/>
  <result pre="has been sequenced by worldwide scholars especially in China. A" exact="total" post="of 9556 SARSâ€�CoVâ€�2 genome sequences have been uploaded in"/>
  <result pre="genome and amino acid sequence will contribute greatly to the" exact="viral" post="classification and traceability, rapid nucleic acid detection of patients"/>
  <result pre="acid detection of patients and understanding of the mechanism of" exact="viral infection" post="and transmission. Especially, the clear viral sequence data could"/>
  <result pre="detection of patients and understanding of the mechanism of viral" exact="infection" post="and transmission. Especially, the clear viral sequence data could"/>
  <result pre="the mechanism of viral infection and transmission. Especially, the clear" exact="viral" post="sequence data could directly guide the selection of therapeutic"/>
  <result pre="the original host of SARSâ€�CoVâ€�2. However, there should be an" exact="intermediate" post="host, who transfers the novel coronavirus to human because"/>
  <result pre="bat virus Batâ€�CoV RaTG3 has minor difference.23, 25 The suspicious" exact="intermediate" post="host has been suggested to be the pangolin by"/>
  <result pre="SARSâ€�COVâ€�2 was easy to infect cats and ferrets, but weakly" exact="infectious" post="to dogs, pigs, chickens and ducks, which could be"/>
  <result pre="which could be important for the traceability of the SARSâ€�COVâ€�2.27" exact="Multiple" post="sequence analysis studies have shown that the genome sequences"/>
  <result pre="these SARSâ€�CoVâ€�2 originated from the same ancestor within a very" exact="short" post="period.23 Despite the low heterogeneity, the number of viral"/>
  <result pre="very short period.23 Despite the low heterogeneity, the number of" exact="viral" post="genome variants will consistently increase with the continuous spread"/>
  <result pre="A deletion of eight amino acid has been reported in" exact="viral" post="polyprotein 1ab (pp1ab) protein, encoded by ORF1ab gene of"/>
  <result pre="(amino acid position 9659), respectively, and both mutations could confer" exact="lower" post="stability of the protein structures.30 Another two mutations of"/>
  <result pre="to be more aggressive and contagious. By analysis of 160" exact="complete" post="human SARSâ€�CoVâ€�2 genomes, researchers from the University of Cambridge"/>
  <result pre="SARSâ€�CoVâ€�2 is generally low and there is no evidence that" exact="viral" post="recombination has occurred. Moreover, many countries have not published"/>
  <result pre="genetics,Â a method of synthesizing viruses by cloning a known" exact="viral" post="genome sequence. This method can provide researchers with infectious"/>
  <result pre="known viral genome sequence. This method can provide researchers with" exact="infectious" post="virus strains without valuable clinical samples and is an"/>
  <result pre="valuable clinical samples and is an attractive alternative to obtain" exact="infectious" post="virus strains.34 3.2 The receptor of SARSâ€�CoVâ€�2: Angiotensin converting"/>
  <result pre="that SARSâ€�CoVâ€�2, like SARSâ€�CoV, invades cells through the receptor ACE2." exact="Viral" post="infectivity studies using HeLa cells with and without ACE2"/>
  <result pre="host cells by binding ACE2 receptor. ACE2 belongs to a" exact="type I" post="membrane protein expressed highly in lungs, oesophagus upper and"/>
  <result pre="a type I membrane protein expressed highly in lungs, oesophagus" exact="upper" post="and stratified epithelial cells, intestine, absorptive enterocytes from ileum"/>
  <result pre="membrane protein expressed highly in lungs, oesophagus upper and stratified" exact="epithelial" post="cells, intestine, absorptive enterocytes from ileum and colon, cholangiocytes,"/>
  <result pre="be potential to be invaded by SARSâ€�CoVâ€�2.43 The interaction between" exact="viral" post="S protein and cell surface receptor ACE2 could activate"/>
  <result pre="of coagulation system, continuous inflammatory response and the occurrence of" exact="acute" post="kidney injury, which could be involved into the pathogenesis"/>
  <result pre="coagulation system, continuous inflammatory response and the occurrence of acute" exact="kidney injury," post="which could be involved into the pathogenesis of COVIDâ€�19"/>
  <result pre="were found to have the unique pathological feature presenting as" exact="bilateral" post="diffuse alveolar damage with cellular fibromyxoid exudates. Interstitial mononuclear"/>
  <result pre="found to have the unique pathological feature presenting as bilateral" exact="diffuse" post="alveolar damage with cellular fibromyxoid exudates. Interstitial mononuclear inflammatory"/>
  <result pre="presenting as bilateral diffuse alveolar damage with cellular fibromyxoid exudates." exact="Interstitial" post="mononuclear inflammatory infiltrates dominated by lymphocytes were seen in"/>
  <result pre="were seen in both lungs, and multinucleated syncytial cells with" exact="atypical" post="enlarged pneumocytes characterized by large nuclei, amphophilic granular cytoplasm"/>
  <result pre="and prominent nucleoli were identified in the intraâ€�alveolar spaces, showing" exact="viral" post="cytopathicâ€�like changes.46 5 CLINICAL FEATURES COVIDâ€�19 is characterized by"/>
  <result pre="CLINICAL FEATURES COVIDâ€�19 is characterized by fever, weakness, dry cough," exact="muscle" post="soreness and dyspnoea. According to the study based on"/>
  <result pre="patients with dizziness. Meanwhile, about 23.7% of the patients had" exact="hypertension" post="or other underlying comorbidities.9, 21 A survey of 138"/>
  <result pre="comorbidities with 31.2% (43) hypertension, 10.1% (14) diabetes, 14.5% (20)" exact="cardiovascular disease" post="and 7.2% (10) malignant.45 There are many COVIDâ€�19 risk"/>
  <result pre="with 31.2% (43) hypertension, 10.1% (14) diabetes, 14.5% (20) cardiovascular" exact="disease" post="and 7.2% (10) malignant.45 There are many COVIDâ€�19 risk"/>
  <result pre="with the higher incidence of older people. High Sequential Organ" exact="Failure" post="Assessment (SOFA) score and Dâ€�dimer &amp;gt;1Â Î¼g/L are also"/>
  <result pre="group and SARSâ€�CoV, which showed O blood group with a" exact="lower" post="infection chance and antiâ€�A antibodies specifically inhibit the adhesion"/>
  <result pre="and SARSâ€�CoV, which showed O blood group with a lower" exact="infection" post="chance and antiâ€�A antibodies specifically inhibit the adhesion of"/>
  <result pre="the detailed mechanism. In the early stage of COVIDâ€�19, the" exact="total" post="number of peripheral blood leucocytes was normal or decreased"/>
  <result pre="In the early stage of COVIDâ€�19, the total number of" exact="peripheral" post="blood leucocytes was normal or decreased and the lymphocyte"/>
  <result pre="was decreased. In some patients, liver enzyme, lactate dehydrogenase (LDH)," exact="muscle" post="enzyme, aspartate transaminase level and myoglobin were increased.53 The"/>
  <result pre="severe COVIDâ€�19, whereas the percentage of naÃ¯ve T cells increased.4" exact="Pneumonia" post="is the typical symptom of COVIDâ€�19, and the character"/>
  <result pre="is the typical symptom of COVIDâ€�19, and the character of" exact="pulmonary" post="image from highâ€�resolution computed tomography (HRCT) includes multiple small"/>
  <result pre="in both lungs and so on.9, 54 In severe cases," exact="pulmonary" post="consolidation may occur whereas pleural effusion is rare.54, 55"/>
  <result pre="on.9, 54 In severe cases, pulmonary consolidation may occur whereas" exact="pleural" post="effusion is rare.54, 55 6 COVIDâ€�19 AND COMPLICATIONS 6.1"/>
  <result pre="is rare.54, 55 6 COVIDâ€�19 AND COMPLICATIONS 6.1 COVIDâ€�19 and" exact="cardiovascular" post="system A study of 41 patients diagnosed with COVIDâ€�19"/>
  <result pre="were admitted to the ICU, accounting for 31% of the" exact="total" post="ICU patients.2 In a study of 138 COVIDâ€�19 patients"/>
  <result pre="systematic review and metaâ€�analysis for 1813 COVIDâ€�19 patients indicated that" exact="cardiovascular disease" post="and hypertension were strongly predictive for both severe disease"/>
  <result pre="review and metaâ€�analysis for 1813 COVIDâ€�19 patients indicated that cardiovascular" exact="disease" post="and hypertension were strongly predictive for both severe disease"/>
  <result pre="metaâ€�analysis for 1813 COVIDâ€�19 patients indicated that cardiovascular disease and" exact="hypertension" post="were strongly predictive for both severe disease and ICU"/>
  <result pre="cardiovascular disease and hypertension were strongly predictive for both severe" exact="disease" post="and ICU admission. However, they found that COPD was"/>
  <result pre="COPD was the most strongly predictive comorbidity for both severe" exact="disease" post="(pOR 6.42, 95% CI 2.44â€�16.9) and ICU admission (pOR"/>
  <result pre="CI 6.56â€�48.2). Studies have found that patients with the underlying" exact="cardiovascular" post="diseases account for a large proportion of COVIDâ€�19 patients."/>
  <result pre="99 COVIDâ€�19 cases indicated that around 40 per cent had" exact="cardiovascular" post="and cerebrovascular diseases.6 In one study of 138 patients,"/>
  <result pre="clinical characteristics of 140 COVIDâ€�19 patients and found that hypertension," exact="diabetes" post="and cardiovascular and cerebrovascular diseases were the most common"/>
  <result pre="of 140 COVIDâ€�19 patients and found that hypertension, diabetes and" exact="cardiovascular" post="and cerebrovascular diseases were the most common underlying diseases"/>
  <result pre="it is important to improve the vigilance of patients with" exact="cardiovascular" post="diseases. Multiple evidences suggest that SARSâ€�CoVâ€�2 infects host cells"/>
  <result pre="important to improve the vigilance of patients with cardiovascular diseases." exact="Multiple" post="evidences suggest that SARSâ€�CoVâ€�2 infects host cells by binding"/>
  <result pre="host cells by binding ACE2 receptor widely expressed in the" exact="cardiovascular" post="system.36 Therefore, ACE2â€�related signalling pathway may play a crucial"/>
  <result pre="be another mechanism of cardiac injury.2 On the other hand," exact="pneumonia" post="caused by SARSâ€�CoVâ€�2 can lead to respiratory dysfunction and"/>
  <result pre="the other hand, pneumonia caused by SARSâ€�CoVâ€�2 can lead to" exact="respiratory" post="dysfunction and hypoxaemia, which can also bring about cardiomyocyte"/>
  <result pre="A study of 1590 COVIDâ€�19 patients indicated that patients with" exact="cancer" post="had a higher risk of COVIDâ€�19 (1% vs 0.29%)"/>
  <result pre="Current evidence remains insufficient to explain a conclusive association between" exact="cancer" post="and COVIDâ€�19. However, a recent communication in the Lancet"/>
  <result pre="current evidence is insufficient to explain the conclusive association between" exact="cancer" post="and COVIDâ€�19.59 6.3 COVIDâ€�19 and kidney Data from a"/>
  <result pre="patients found that the incidence of creatinine &amp;gt;133 micromol/L and" exact="acute" post="kidney injury (AKI) were 4.3% and 2.9% in severe"/>
  <result pre="found that the incidence of creatinine &amp;gt;133 micromol/L and acute" exact="kidney injury" post="(AKI) were 4.3% and 2.9% in severe patients, respectively,"/>
  <result pre="have proteinuria haematuria, 26.9% have haematuria and the prevalence of" exact="elevated serum" post="creatinine and blood urea nitrogen were 15.5% and 14.1%,"/>
  <result pre="occurred in 3.2% patients. Cox proportional hazard regression confirmed that" exact="elevated serum" post="creatinine, elevated urea nitrogen, AKI, proteinuria and haematuria were"/>
  <result pre="TNFâ€�Î±, suggesting that the cytokine storm may be associated with" exact="disease" post="severity.2 7 DETECTION METHODS 7.1 Nucleic acid detection Detect"/>
  <result pre="and N genes are different.63 In S gene, SARSâ€�CoVâ€�2 shows" exact="lower" post="GC% and higher AT% than SARSâ€�CoV and MERS. As"/>
  <result pre="probe based realâ€�time RTâ€�PCR to detect SARSâ€�CoVâ€�2 nucleic acid in" exact="respiratory" post="specimens or blood specimens (TableÂ 1). Table 1 The"/>
  <result pre="test in the specimens of pharyngeal swab, sputum and other" exact="lower" post="respiratory tract secretions, blood, faeces by realâ€�time RTâ€�PCR and"/>
  <result pre="in the specimens of pharyngeal swab, sputum and other lower" exact="respiratory" post="tract secretions, blood, faeces by realâ€�time RTâ€�PCR and NGS."/>
  <result pre="secretions, blood, faeces by realâ€�time RTâ€�PCR and NGS. Sputum and" exact="lower" post="respiratory tract secretions are more accurate; 2. Serological test:"/>
  <result pre="blood, faeces by realâ€�time RTâ€�PCR and NGS. Sputum and lower" exact="respiratory" post="tract secretions are more accurate; 2. Serological test: novel"/>
  <result pre="increases 4 times or more in recovery phase compared to" exact="acute" post="phase. Nucleic acid test in the specimens of pharyngeal"/>
  <result pre="test in the specimens of pharyngeal swab, sputum and other" exact="lower" post="respiratory tract secretions, blood. To make sure the accurate"/>
  <result pre="in the specimens of pharyngeal swab, sputum and other lower" exact="respiratory" post="tract secretions, blood. To make sure the accurate result,"/>
  <result pre="accurate result, recommend taking the sputum and secretions from the" exact="lower" post="respiration track by tracheal intubation. Nucleic acid test in"/>
  <result pre="test in the specimens of pharyngeal swab, sputum and other" exact="lower" post="respiratory tract secretions, blood and faeces. Nucleic acid test"/>
  <result pre="in the specimens of pharyngeal swab, sputum and other lower" exact="respiratory" post="tract secretions, blood and faeces. Nucleic acid test in"/>
  <result pre="test in the specimens of pharyngeal swab, sputum and other" exact="lower" post="respiratory tract secretions, blood. NA NA Diagnosis confirmation The"/>
  <result pre="in the specimens of pharyngeal swab, sputum and other lower" exact="respiratory" post="tract secretions, blood. NA NA Diagnosis confirmation The suspected"/>
  <result pre="increases 4 times or more in recovery phase compared to" exact="acute" post="phase The suspected case, who have one of the"/>
  <result pre="Nucleic acid test is positive by realâ€�time RTâ€�PCR in the" exact="respiratory" post="or blood specimens. 2. Have high identity with the"/>
  <result pre="with the known novel coronavirus sequence by NGS in the" exact="respiratory" post="or blood specimens The suspected case, who have one"/>
  <result pre="Nucleic acid test is positive by realâ€�time RTâ€�PCR in the" exact="respiratory" post="or blood specimens. 2. Have high identity with the"/>
  <result pre="with the known novel coronavirus sequence by NGS in the" exact="respiratory" post="or blood specimens No change Conform to the suspected"/>
  <result pre="realâ€�time RTâ€�PCR in the specimens of sputum, pharyngeal swab and" exact="lower" post="respiratory tract secretions. 2.Have high identity with the known"/>
  <result pre="RTâ€�PCR in the specimens of sputum, pharyngeal swab and lower" exact="respiratory" post="tract secretions. 2.Have high identity with the known novel"/>
  <result pre="by NGS in the specimens of sputum, pharyngeal swab and" exact="lower" post="respiratory tract secretions Report system The suspected case can"/>
  <result pre="NGS in the specimens of sputum, pharyngeal swab and lower" exact="respiratory" post="tract secretions Report system The suspected case can be"/>
  <result pre="at least 24Â h) in the specimens of sputum and" exact="respiratory" post="tract secretion etc No change No change No change"/>
  <result pre="of sampling time is at least 1Â d) in the" exact="respiratory" post="tract specimens. Note The italicized text indicates the increased"/>
  <result pre="previous version. (C) John Wiley &amp;amp; Sons, Ltd, Although the" exact="viral" post="nucleic acid test is currently the standard method for"/>
  <result pre="the nicking endonuclease amplification reaction (NEAR) technology, which could get" exact="bacterial" post="or virus test results within 13Â minutes or less"/>
  <result pre="speed up the population screening and COVIDâ€�19 patient identification.67 7.2" exact="Antibody" post="detection Rapid and accurate detection of SARSâ€�CoVâ€�2â€�specific antibodies in"/>
  <result pre="acid testing. IgM provides the first line of defence during" exact="viral infection," post="followed by the production of IgG that is important"/>
  <result pre="and immunological memory.68 Moreover, positive IgM antibody often indicates an" exact="acute" post="phase of infection while positive IgG antibody indicates late"/>
  <result pre="Moreover, positive IgM antibody often indicates an acute phase of" exact="infection" post="while positive IgG antibody indicates late or previous infection."/>
  <result pre="IgG can also provide information on the time course of" exact="virus infection." post="However, since serological test was gradually established, its diagnostic"/>
  <result pre="recognized in â€˜Diagnosis and Treatment Guideline of the Novel Coronavirus" exact="Pneumonia" post="(Version 7)â€™ of China (TableÂ 1). According to a"/>
  <result pre="(TableÂ 1). According to a recent study, an increase of" exact="viral" post="antibodies can be seen in almost all patients on"/>
  <result pre="IgG were 81% and 100%, respectively.69 Therefore, dynamic monitoring of" exact="viral" post="IgM or IgG can be considered as a complementary"/>
  <result pre="accelerate the search for an effective treatment.73 So far, a" exact="total" post="of 1119 clinical trials have been registered to evaluate"/>
  <result pre="also expected to inhibit the overactivation of immune system, control" exact="acute" post="pulmonary inflammation and improve the endogenous reparation for injured"/>
  <result pre="expected to inhibit the overactivation of immune system, control acute" exact="pulmonary" post="inflammation and improve the endogenous reparation for injured tissue,74,"/>
  <result pre="brings new hope for the treatment of novel coronavirus infectionâ€�related" exact="acute" post="respiratory distress syndrome. A clinical trial (NCT04252118) of COVIDâ€�19"/>
  <result pre="new hope for the treatment of novel coronavirus infectionâ€�related acute" exact="respiratory" post="distress syndrome. A clinical trial (NCT04252118) of COVIDâ€�19 stem"/>
  <result pre="way. 8.1 Antiviral drugs Antiviral drugs can be classified as" exact="viral" post="protease inhibitors, viral nucleoside analogs and agents that disrupt"/>
  <result pre="drugs Antiviral drugs can be classified as viral protease inhibitors," exact="viral" post="nucleoside analogs and agents that disrupt the interaction mechanism"/>
  <result pre="against COVIDâ€�19 Drug Antiviral mechanism References Evidences TherapeuticÂ effect Lopinavir/Ritonavir" exact="Viral" post="protease inhibitors Kim et al 2020 Clinical case study"/>
  <result pre="et al 2020 Clinical case study Did not decease the" exact="viral" post="load and have gastrointestinal side effect Cao et al"/>
  <result pre="al 2020 Clinical trial No benefit was observed in hospitalized" exact="adult" post="patients with severe Covidâ€�19 Disulfiram Li and De Clercq"/>
  <result pre="In vitro Has inhibitory activity against SARS and MERS Favipiravir" exact="Viral" post="nucleoside analogs Wang et al 2020 In vitro Favipiravir"/>
  <result pre="Wang et al 2020 In vitro Favipiravir could suppress SARSâ€�COVâ€�2" exact="infection" post="at a high concentration Remdesivir Holshue etÂ al 2020"/>
  <result pre="inhibitors Wang et al 2020 In vitro Suppression of COVIDâ€�19" exact="pneumonia" post="exacerbation, reduction of symptom duration, Gao et al 2020"/>
  <result pre="Clinical trial Have apparent efficacy and acceptable safety against COVIDâ€�19â€�associated" exact="pneumonia" post="in multicentre clinical trials conducted in China. Hydroxychloroquine Wang"/>
  <result pre="al 2020 Clinical trial HydroxychloroquineÂ treatmentÂ is significantly associated with" exact="viral" post="load reduction/disappearance inÂ COVIDâ€�19Â patients and its effect is"/>
  <result pre="et al 2020 In vitro Arbidol can effectively inhibit SARSâ€�CoVâ€�2" exact="infection" post="at a concentration of 10â€�30Â ÂµM Nitazoxanide Wang et"/>
  <result pre="Elfiky 2020 In vitro Tightly combine with SARSâ€�CoVâ€�2 RdRp for" exact="viral" post="clearance Corticosteroids Zhou and Liu 2020 ClinicalÂ experience Lowâ€�dose"/>
  <result pre="inhibit the SARSâ€�CoVâ€�2 (C) John Wiley &amp;amp; Sons, Ltd, 8.2" exact="Viral" post="protease inhibitors Lopinavir/ritonavir and disulfiram are the wellâ€�known viral"/>
  <result pre="8.2 Viral protease inhibitors Lopinavir/ritonavir and disulfiram are the wellâ€�known" exact="viral" post="protease inhibitors and have been shown to be effective"/>
  <result pre="that they did not have a significant decrease of the" exact="viral" post="load after lopinavir/ritonavir therapy, but experienced gastrointestinal discomfort as"/>
  <result pre="of the viral load after lopinavir/ritonavir therapy, but experienced gastrointestinal" exact="discomfort" post="as a side effect.78 Recent published result of the"/>
  <result pre="COVIDâ€�19 patients.79 Disulfiram is a drug for the treatment of" exact="alcohol dependence," post="and studies have confirmed its inhibitory activity against SARS"/>
  <result pre="and MERS in cell cultures instead of clinical situation.72 8.3" exact="Viral" post="nucleoside analogs Favipiravir has shown an effective inhibition on"/>
  <result pre="nucleoside analogs Favipiravir has shown an effective inhibition on Ebola," exact="yellow fever," post="chikungunya, norovirus and enterovirus by restraining RNAâ€�dependent RNA polymerase"/>
  <result pre="viruses.80 A recent study demonstrated that Favipiravir could suppress SARSâ€�CoVâ€�2" exact="infection" post="at a high concentration (halfâ€�maximal effective concentration (EC50)Â =Â"/>
  <result pre="(CC50) &amp;gt;400Â Î¼mol/L, selectivity index (SI)&amp;gt; 6.46).81 Remdesivir, approved for" exact="HIV infection" post="treatment, has been used to cure a COVIDâ€�19 patient"/>
  <result pre="&amp;gt;400Â Î¼mol/L, selectivity index (SI)&amp;gt; 6.46).81 Remdesivir, approved for HIV" exact="infection" post="treatment, has been used to cure a COVIDâ€�19 patient"/>
  <result pre="(NCT04252664 and NCT04257656).72, 82 The efficacy of nucleotide analogs requires" exact="viral" post="RdRps to recognize and successfully incorporate the active form"/>
  <result pre="was superior to the control group in suppression of COVIDâ€�19" exact="pneumonia" post="exacerbation, reduction of symptom duration and delay of viral"/>
  <result pre="COVIDâ€�19 pneumonia exacerbation, reduction of symptom duration and delay of" exact="viral" post="clearance without severe side effects,85 but no specific primary"/>
  <result pre="of viral clearance without severe side effects,85 but no specific" exact="primary" post="or secondary endâ€�points. For clinicians accustomed to it, hydroxychloroquine"/>
  <result pre="clearance without severe side effects,85 but no specific primary or" exact="secondary" post="endâ€�points. For clinicians accustomed to it, hydroxychloroquine may be"/>
  <result pre="At present, high quality, adequately powered randomized clinical trials in" exact="primary" post="and secondary care settings are urgently required to guide"/>
  <result pre="high quality, adequately powered randomized clinical trials in primary and" exact="secondary" post="care settings are urgently required to guide policymakers and"/>
  <result pre="vitro study has revealed that Arbidol could effectively inhibit SARSâ€�CoVâ€�2" exact="infection" post="at a concentration of 10â€�30Â Âµmol/L, which brought arbidol"/>
  <result pre="risk of mortality significantly.96 During the outbreak of Ebola virus" exact="disease" post="(EVD) in 2014, the use of convalescent plasma collected"/>
  <result pre="effect of convalescent plasma therapy for patients with Middle East" exact="respiratory" post="syndrome coronavirus infection was reported98 and no severe adverse"/>
  <result pre="of convalescent plasma therapy for patients with Middle East respiratory" exact="syndrome" post="coronavirus infection was reported98 and no severe adverse events"/>
  <result pre="plasma therapy for patients with Middle East respiratory syndrome coronavirus" exact="infection" post="was reported98 and no severe adverse events occurred among"/>
  <result pre="showed that the effects of this antibody were not only" exact="limited" post="to free viral clearance and block new infection, but"/>
  <result pre="effects of this antibody were not only limited to free" exact="viral" post="clearance and block new infection, but also could accelerate"/>
  <result pre="but the following principles should be followed: (a) the patient's" exact="disease" post="course should not exceed 3Â weeks or has viraemia"/>
  <result pre="have from the original outbreak China to outside regions, especially" exact="American" post="and Europe. Fortunately, we already accumulated some knowledge about"/>
  <result pre="ZhangD, WangW, et al. A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019. N Engl J Med. 2020;382(8):727â€�733.31978945 2HuangC,"/>
  <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507â€�513.32007143 7WuZ,"/>
  <result pre="7WuZ, McGooganJM. Characteristics of and Important Lessons From the Coronavirus" exact="Disease" post="2019 (COVIDâ€�19) Outbreak in China. JAMA. 2020;323(13):1239. 8LiQ, GuanX,"/>
  <result pre="2020;382(13):1199â€�1207.31995857 9GuanWJ, NiZY, HuY, et al. Clinical characteristics of coronavirus" exact="disease" post="2019 in China. N Engl J Med. 2020. 10VerityR,"/>
  <result pre="OkellLC, DorigattiI, et al. Estimates of the severity of coronavirus" exact="disease" post="2019: a modelâ€�based analysis. The Lancet Infect Dis. 202010.1016/S1473-3099(20)30243-7"/>
  <result pre="Romeroâ€�SeversonE, HengartnerN, KeR. High contagiousness and rapid spread of severe" exact="acute" post="respiratory syndrome coronavirus 2. Emerg Infect Dis. 2020;26(7). 10.3201/eid2607.200282"/>
  <result pre="HengartnerN, KeR. High contagiousness and rapid spread of severe acute" exact="respiratory" post="syndrome coronavirus 2. Emerg Infect Dis. 2020;26(7). 10.3201/eid2607.200282 12BrebanR,"/>
  <result pre="KeR. High contagiousness and rapid spread of severe acute respiratory" exact="syndrome" post="coronavirus 2. Emerg Infect Dis. 2020;26(7). 10.3201/eid2607.200282 12BrebanR, RiouJ,"/>
  <result pre="2020;26(7). 10.3201/eid2607.200282 12BrebanR, RiouJ, FontanetA. Interhuman transmissibility of Middle East" exact="respiratory" post="syndrome coronavirus: estimation of pandemic risk. Lancet. 2013;382(9893):694â€�699.23831141 13FangY,"/>
  <result pre="10.3201/eid2607.200282 12BrebanR, RiouJ, FontanetA. Interhuman transmissibility of Middle East respiratory" exact="syndrome" post="coronavirus: estimation of pandemic risk. Lancet. 2013;382(9893):694â€�699.23831141 13FangY, NieY,"/>
  <result pre="J Med Virol. 2020;92(6):645â€�659.32141624 14ZouL, RuanF, HuangM, et al. SARSâ€�CoVâ€�2" exact="viral" post="load in upper respiratory specimens of infected patients. N"/>
  <result pre="2020;92(6):645â€�659.32141624 14ZouL, RuanF, HuangM, et al. SARSâ€�CoVâ€�2 viral load in" exact="upper" post="respiratory specimens of infected patients. N Engl J Med."/>
  <result pre="14ZouL, RuanF, HuangM, et al. SARSâ€�CoVâ€�2 viral load in upper" exact="respiratory" post="specimens of infected patients. N Engl J Med. 2020;382(12):1177â€�1179.32074444"/>
  <result pre="J Med. 2020;382(12):1177â€�1179.32074444 15LuCW, LiuXF, JiaZF. 2019â€�nCoV transmission through the" exact="ocular" post="surface must not be ignored. Lancet. 2020;395(10224):e39.32035510 16OngSWX, TanYK,"/>
  <result pre="Air, surface environmental, and personal protective equipment contamination by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARSâ€�CoVâ€�2) from a symptomatic patient."/>
  <result pre="surface environmental, and personal protective equipment contamination by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARSâ€�CoVâ€�2) from a symptomatic patient. JAMA."/>
  <result pre="environmental, and personal protective equipment contamination by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARSâ€�CoVâ€�2) from a symptomatic patient. JAMA. 2020;323(16):1610â€�1612."/>
  <result pre="by severe acute respiratory syndrome coronavirus 2 (SARSâ€�CoVâ€�2) from a" exact="symptomatic" post="patient. JAMA. 2020;323(16):1610â€�1612. 10.1001/jama.2020.3227 17ChenH, GuoJ, WangC, et al."/>
  <result pre="al. Clinical characteristics and intrauterine vertical transmission potential of COVIDâ€�19" exact="infection" post="in nine pregnant women: a retrospective review of medical"/>
  <result pre="20HuangR, XiaJ, ChenY, ShanC, WuC. A family cluster of SARSâ€�CoVâ€�2" exact="infection" post="involving 11 patients in Nanjing. Lancet Infect Dis. 2020."/>
  <result pre="ZhaoS, YuB, et al. A new coronavirus associated with human" exact="respiratory" post="disease in China. Nature. 2020;579(7798):265â€�269.32015508 22CeraoloC, GiorgiFM. Genomic variance"/>
  <result pre="YuB, et al. A new coronavirus associated with human respiratory" exact="disease" post="in China. Nature. 2020;579(7798):265â€�269.32015508 22CeraoloC, GiorgiFM. Genomic variance of"/>
  <result pre="Infect Genetics Evolut. 2020;79:104212. 25ZhouP, YangXL, WangXG, et al. A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="et al. Evolutionary analysis of SARSâ€�CoVâ€�2: how mutation of Nonâ€�Structural" exact="Protein" post="6 (NSP6) could affect viral autophagy. J Infect. 2020."/>
  <result pre="SARSâ€�CoVâ€�2: how mutation of Nonâ€�Structural Protein 6 (NSP6) could affect" exact="viral" post="autophagy. J Infect. 2020. 31WangC, LiuZ, ChenZ, et al."/>
  <result pre="prefusion conformation. Science. 2020;367(6483):1260â€�1263.32075877 38YanR, ZhangY, LiY, XiaL, GuoY, ZhouQ." exact="Structural" post="basis for the recognition of SARSâ€�CoVâ€�2 by fullâ€�length human"/>
  <result pre="26. 40DingY, HeL, ZhangQ, et al. Organ distribution of severe" exact="acute" post="respiratory syndrome (SARS) associated coronavirus (SARSâ€�CoV) in SARS patients:"/>
  <result pre="40DingY, HeL, ZhangQ, et al. Organ distribution of severe acute" exact="respiratory" post="syndrome (SARS) associated coronavirus (SARSâ€�CoV) in SARS patients: implications"/>
  <result pre="HeL, ZhangQ, et al. Organ distribution of severe acute respiratory" exact="syndrome" post="(SARS) associated coronavirus (SARSâ€�CoV) in SARS patients: implications for"/>
  <result pre="Med. 2020;382(10):929â€�936.32004427 43FanC, LiK, DingY, LuWL, WangJ. ACE2 Expression in" exact="Kidney" post="and Testis May Cause Kidney and Testis Damage After"/>
  <result pre="LuWL, WangJ. ACE2 Expression in Kidney and Testis May Cause" exact="Kidney" post="and Testis Damage After 2019â€�nCoV Infection. 2020: published online"/>
  <result pre="Compensation of ACE2 function for possible clinical management of 2019â€�nCoVâ€�induced" exact="acute" post="lung injury. Virol Sin. 2020. 45WangD, HuB, HuC, et"/>
  <result pre="Clinical characteristics of 138 hospitalized patients With 2019 novel coronavirusâ€&quot;infected" exact="pneumonia" post="in Wuhan, China. JAMA. 2020;323(11):1061. 46XuZ, ShiL, WangY, et"/>
  <result pre="ShiL, WangY, et al. Pathological findings of COVIDâ€�19 associated with" exact="acute" post="respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420â€�422.32085846 47ZhouF, YuT,"/>
  <result pre="WangY, et al. Pathological findings of COVIDâ€�19 associated with acute" exact="respiratory" post="distress syndrome. Lancet Respir Med. 2020;8(4):420â€�422.32085846 47ZhouF, YuT, DuR,"/>
  <result pre="et al. Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVIDâ€�19 in Wuhan, China: a retrospective cohort"/>
  <result pre="2020;395(10227):846â€�848.32151325 50ZhaoJ, YangY, HuangH, et al. Relationship between the ABO" exact="Blood" post="Group and the COVIDâ€�19 Susceptibility. 2020: published online Mar"/>
  <result pre="16. 51ChengY, ChengG, ChuiCH, et al. ABO blood group and" exact="susceptibility to" post="severe acute respiratory syndrome. JAMA. 2005;293(12):1450â€�1451. 52GuillonP, ClementM, SebilleV,"/>
  <result pre="ChuiCH, et al. ABO blood group and susceptibility to severe" exact="acute" post="respiratory syndrome. JAMA. 2005;293(12):1450â€�1451. 52GuillonP, ClementM, SebilleV, et al."/>
  <result pre="et al. ABO blood group and susceptibility to severe acute" exact="respiratory" post="syndrome. JAMA. 2005;293(12):1450â€�1451. 52GuillonP, ClementM, SebilleV, et al. Inhibition"/>
  <result pre="ZengW, et al. Chest CT findings in patients with coronavirus" exact="disease" post="2019 and its relationship with clinical features. Invest Radiol."/>
  <result pre="China. Allergy. 2020. 57ZhengYY, MaYT, ZhangJY, XieX. COVIDâ€�19 and the" exact="cardiovascular" post="system. Nat Rev Cardiol. 2020. 58LiangW, GuanW, ChenR, et"/>
  <result pre="system. Nat Rev Cardiol. 2020. 58LiangW, GuanW, ChenR, et al." exact="Cancer" post="patients in SARSâ€�CoVâ€�2 infection: a nationwide analysis in China."/>
  <result pre="Lancet Oncol. 2020;21(4):e180.32142622 60LiZ, WuM, YaoJ, et al. Caution on" exact="Kidney" post="Dysfunctions of COVIDâ€�19 Patients. SSRN Electr J. 2020: published"/>
  <result pre="Oncol. 2020;21(4):e180.32142622 60LiZ, WuM, YaoJ, et al. Caution on Kidney" exact="Dysfunctions" post="of COVIDâ€�19 Patients. SSRN Electr J. 2020: published online"/>
  <result pre="2020: published online Feb 12. 61ChengY, LuoR, WangK, et al." exact="Kidney" post="impairment is associated with inâ€�hospital death of COVIDâ€�19 patients."/>
  <result pre="CoVs to SARSâ€�CoVâ€�2: moving toward more biased codon usage in" exact="viral" post="structural and nonstructural genes. J Med Virol. 2020;92(6):660â€�666.32159237 65collab:"/>
  <result pre="application of a rapid IgMâ€�IgG combined antibody test for SARSâ€�CoVâ€�2" exact="infection" post="diagnosis. J Med Virol. 2020. 67KanwarN, MichaelJ, DoranK, MontgomeryE,"/>
  <result pre="PanJ, SuY, WangB, GeJ. SARSâ€�CoVâ€�2 lgM/lgG antibody detection confirms the" exact="infection" post="after three negative nucleic acid detection. J Cell Mol"/>
  <result pre="74AbreuSC, AntunesMA, PelosiP, MoralesMM, RoccoPR. Mechanisms of cellular therapy in" exact="respiratory" post="diseases. Intensive Care Med. 2011;37(9):1421â€�1431.21656291 75SilvaLHA, AntunesMA, Dos SantosCC,"/>
  <result pre="to improve the therapeutic effects of mesenchymal stromal cells in" exact="respiratory" post="diseases. Stem Cell Res Ther. 2018;9(1):45.29482654 76ChanKS, LaiST, ChuCM,"/>
  <result pre="Ther. 2018;9(1):45.29482654 76ChanKS, LaiST, ChuCM, et al. Treatment of severe" exact="acute" post="respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort"/>
  <result pre="2018;9(1):45.29482654 76ChanKS, LaiST, ChuCM, et al. Treatment of severe acute" exact="respiratory" post="syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study."/>
  <result pre="76ChanKS, LaiST, ChuCM, et al. Treatment of severe acute respiratory" exact="syndrome" post="with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong"/>
  <result pre="Am J Chin Med. 2019;2020:1â€�26. 78KimJY, KoJH, KimY, et al." exact="Viral" post="load kinetics of SARSâ€�CoVâ€�2 infection in first two patients"/>
  <result pre="78KimJY, KoJH, KimY, et al. Viral load kinetics of SARSâ€�CoVâ€�2" exact="infection" post="in first two patients in Korea. J Korean Med"/>
  <result pre="Res. 2020;30(3):269â€�271.32020029 82DongL, HuS, GaoJ. Discovering drugs to treat coronavirus" exact="disease" post="2019 (COVIDâ€�19). Drug Discov Ther. 2020;14(1):58â€�60.32147628 83GaoY, YanL, HuangY,"/>
  <result pre="phosphate has shown apparent efficacy in treatment of COVIDâ€�19 associated" exact="pneumonia" post="in clinical studies. Bioscience Trends. 2020;14(1):72â€�73.32074550 86ColsonP, RolainJM, LagierJC,"/>
  <result pre="Agents. 2020;105949.32205204 89GuastalegnameM, ValloneA. Could chloroquine/hydroxychloroquine be harmful in coronavirus" exact="disease" post="2019 (COVIDâ€�19) treatment?Clin Infect Dis. 2020. 90GbinigieK, FrieK. Should"/>
  <result pre="GriffinI, TuckerC, et al. Baricitinib as potential treatment for 2019â€�nCoV" exact="acute" post="respiratory disease. Lancet. 2020;395(10223):e30â€�e31.32032529 94ZhangDH, WuKL, ZhangX, DengSQ, PengB."/>
  <result pre="TuckerC, et al. Baricitinib as potential treatment for 2019â€�nCoV acute" exact="respiratory" post="disease. Lancet. 2020;395(10223):e30â€�e31.32032529 94ZhangDH, WuKL, ZhangX, DengSQ, PengB. In"/>
  <result pre="mortality in patients with severe pandemic influenza A (H1N1) 2009" exact="virus infection." post="Clin Infect Dis. 2011;52(4):447â€�456.21248066 97collab: World Health Organization ."/>
  <result pre="2011;52(4):447â€�456.21248066 97collab: World Health Organization . Use of Convalescent Whole" exact="Blood" post="or Plasma Collected from Patients Recovered from Ebola Virus"/>
  <result pre="Whole Blood or Plasma Collected from Patients Recovered from Ebola" exact="Virus Disease" post="for Transfusion, as an Empirical Treatment During Outbreaks: Interim"/>
  <result pre="Blood or Plasma Collected from Patients Recovered from Ebola Virus" exact="Disease" post="for Transfusion, as an Empirical Treatment During Outbreaks: Interim"/>
  <result pre="Treatment During Outbreaks: Interim Guidance for National Health Authorities and" exact="Blood" post="Transfusion Services, Version 1.0. World Health Organization2014. 98ArabiY, BalkhyH,"/>
  <result pre="effects of convalescent plasma therapy for patients with Middle East" exact="respiratory" post="syndrome coronavirus infection: a study protocol. SpringerPlus. 2015;4:709.26618098 99LuCL,"/>
  <result pre="of convalescent plasma therapy for patients with Middle East respiratory" exact="syndrome" post="coronavirus infection: a study protocol. SpringerPlus. 2015;4:709.26618098 99LuCL, MurakowskiDK,"/>
  <result pre="bioRxiv. 2020: Publish on 21 March. 103ChangL, YanY, WangL. Coronavirus" exact="disease" post="2019: coronaviruses and blood safety. Transfus Med Rev. 2020."/>
  <result pre="BCG may provide immune boost against coronavirus, herpes, and other" exact="viral" post="infections. Medicalxpress News. 2020https://medicalxpress.com. Accessed March 23."/>
 </snippets>
</snippetsTree>
